Arthur F Kavanaugh MD

Professor, Medicine, UCSD School of Medicine

9350 Campus Point DrMail Code 0997La Jolla, CA 92037
Phone+1 858-657-7044
Fax+1 858-657-7045

Dr. Kavanaugh is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kavanaugh's full profile Already have an account?

Education & Training

University of Texas Southwestern Medical CenterFellowship, Rheumatology, 1989 - 1990
Baylor College of MedicineFellowship, Allergy and Immunology, 1987 - 1989
Baylor College of MedicineResidency, Internal Medicine, 1984 - 1987
Saint Louis University School of MedicineClass of 1984

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1999 - 2027
TX State Medical License 1985 - 2027
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2017

Clinical Trials

Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain
COMPLETED
PHASE3
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Start of enrollment: 2019 Jun 26
TERMINATED
PHASE2

Publications & Presentations

PubMed

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.
Peter C Taylor, Arthur Kavanaugh, Louis Bessette, Bruno Fautrel, Tsutomu Takeuchi
RMD Open. 2026-01-08
5 citations
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study.
Alan Kivitz, Xenofon Baraliakos, Elena Tomaselli Muensterman, Arthur Kavanaugh, Désirée van der Heijde
Annals of the Rheumatic Diseases. 2025-10-01
1 citations
Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta-Analysis.
Thipsukhon Sathapanasiri, Manuel Meraz, Hamraz Mokri, Sajesh K Veettil, Karn Wijarnpreecha
Arthritis Care & Research. 2025-10-01

Lectures

Updates in Rheumatology 2011: Highlights from the ACR and EULAR Meetings
University of California San Diego, La Jolla, California - 12/10/2011

Other

Miscellaneous novel therapies in rheumatoid arthritis
Kavanaugh A, Schur PH, Maini R
http://www.uptodate.com/contents/miscellaneous-novel-therapies-in-rheumatoid-arthritis
UpToDate, Wolters Kluwer Health - 2012-07-11

Press Mentions

PCR: Prevalence, Cost, & Risk (6.27.2025) SaveJune 27th, 2025
Should You Interrupt Arthritis DMARDs During an Infection?April 1st, 2025
Safety of Combo Therapy for Immune-Mediated Inflammatory Diseases Requires CautionApril 1st, 2025